Evidence memo / Neuro & mental health

DSIP (delta sleep-inducing peptide)

Also: DSIP · emideltide

DSIP (delta sleep-inducing peptide) is a small peptide first identified for a possible role in sleep. Most research is older and mixed, looking at sleep, stress, pain, and withdrawal, and its very existence as a natural sleep regulator has been debated. It is not an approved drug and is sold in the gray market for sleep and recovery. The Watchlist boundary is separating its limited, dated research from the sleep and recovery claims made for it today.

Early human signalEarly human signalSafety / regulatory watch

The verdict

Our read at a glance.

Whether DSIP's older and contested research supports the sleep, stress, and recovery claims made for gray-market DSIP products.

The signal
Research on DSIP is mostly older and inconsistent, covering sleep, stress, pain, and withdrawal, with no clear, replicated clinical benefit. Whether it functions as a true natural sleep regulator has been questioned, and it is not approved for any use.
The unknown
Whether DSIP has any reliable effect on sleep or recovery in rigorous trials, and how its dated research applies to gray-market products of uncertain identity.
Our read
An old, contested sleep peptide with thin and inconsistent evidence, not a proven sleep aid. DSIP has a long history of research, but it never produced clear, replicated benefit, so its modern sleep and recovery claims rest on weak ground.

The mechanism

How it works.

DSIP (delta sleep-inducing peptide) is a small nine-amino-acid peptide first isolated from the blood of sleeping rabbits and named for an apparent sleep-promoting effect. It is proposed to act on brain pathways tied to sleep, stress, and pain, but no specific receptor or clear mechanism has been confirmed, and whether it even functions as a natural sleep regulator in the body is disputed. Its effects are hard to pin down precisely because the underlying mechanism is not established.

Safety & regulatory boundary

The consequential part.

DSIP is not an approved drug and is sold as a research chemical, where product identity and quality are uncertain. Its older research is mixed and does not establish sleep, stress, or recovery benefits. It should not be treated as a proven or approved sleep aid, and gray-market products are not the same as any studied preparation.

What's next

What we're watching.

Any modern controlled trials, clarification of its biology, and product-quality findings for gray-market DSIP.

Context

Why this is discussed.

DSIP is marketed for sleep and recovery, and its name and early history give it an aura of being a natural sleep peptide, which people often take as stronger evidence than exists.

The evidence base

20 cited references.

Indexed literature (PubMed)12

Delta sleep-inducing peptide

Pollard BJ et al. · Eur J Anaesthesiol · 2001

Delta-sleep-inducing peptide (DSIP): an update

Graf MV et al. · Peptides · 1986

Delta-sleep-inducing peptide (DSIP): a review

Graf MV et al. · Neurosci Biobehav Rev · 1984

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

Rahman OF et al. · J Am Acad Orthop Surg Glob Res Rev · 2026

Keep reading

Related published memos.